Meet us at Bio€quity 2022 | UGISense will attend Bio€quity 2022, which will take place in 17 – 18 May 2022 in Milan
May 10, 2022
Oligonucleotide Production for Future Blockbuster Applications Is Challenging
April 28, 2022
UGISense and Boehringer Ingelheim enter into an agreement for specific Ugimers™ in animal parasitic diseases
March 15, 2022
UGISense AG Raises its Series B Round to Advance its Oncology Program Towards Pre-clinical and Clinical Development
April 29, 2021
September 11, 2020
16th Annual Meeting of the Oligo Nucleotide Therapeutics Society
UGISense AG secures new financing
June 20, 2018
Dortmund, June 19, 2018 – Following the seed financing round in 2016, UGISense AG has again been able to successfully complete a funding round.
LDC and UGISense AG to Collaborate on New Drug Class
October 10, 2016
Dortmund, October 12, 2016 – Lead Discovery Center GmbH (LDC) and the biotech company UGISense AG are about to initiate a collaboration to jointly develop innovative drugs using the proprietary UgimeresTM antisense platform.